Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
- F Bonino 1, P Marcellin , G K K Lau , S Hadziyannis , R Jin , T Piratvisuth , G Germanidis , C Yurdaydin , M Diago , S Gurel , M-Y Lai , M R Brunetto , P Farci , M Popescu , P McCloud ,
- F Bonino 1, P Marcellin , G K K Lau
- 1University of Pisa and Foundation IRCCS, Policlinico di Milano, Milan, Italy. bonino@med-club.com
- 0University of Pisa and Foundation IRCCS, Policlinico di Milano, Milan, Italy. bonino@med-club.com
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Peginterferon alpha-2a therapy, with or without lamivudine, improved treatment response in chronic hepatitis B patients. Baseline factors like age, gender, ALT, HBV DNA, and genotype significantly predicted outcomes, especially for genotypes B and C.
Area Of Science
- Hepatology
- Virology
- Pharmacology
Background
- Chronic hepatitis B (CHB) remains a significant global health concern.
- Hepatitis B e antigen (HBeAg)-negative CHB treatment aims for sustained biochemical and virological remission.
- Peginterferon alpha-2a and lamivudine are key antiviral therapies for CHB.
Purpose Of The Study
- To evaluate the efficacy of peginterferon alpha-2a with or without lamivudine versus lamivudine monotherapy in HBeAg-negative CHB.
- To identify pre-treatment factors predicting post-treatment response to these therapies.
Main Methods
- A clinical trial involving 518 patients with HBeAg-negative CHB.
- Multivariate logistic regression analyses were used to assess predictors of response.
- Response was defined as normalized ALT and HBV DNA <20,000 copies/ml at 24 weeks post-treatment.
Main Results
- Peginterferon alpha-2a (with or without lamivudine) showed higher response rates than lamivudine alone.
- Younger age, female gender, high baseline ALT, low baseline HBV DNA, and specific HBV genotypes (B/C) predicted better response.
- Genotype D patients responded better to combination therapy than peginterferon alpha-2a monotherapy.
Conclusions
- Pre-treatment factors including baseline ALT, HBV DNA, age, gender, and HBV genotype significantly influence treatment response in CHB.
- HBV genotype is a crucial predictor of sustained response to peginterferon alpha-2a-based therapies at one year post-treatment.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.